Zevra Therapeutics, Inc.
ZVRA
$8.31
$0.374.66%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 225.93% | -16.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 225.93% | -16.95% | |||
| Cost of Revenue | -40.69% | -35.54% | |||
| Gross Profit | 667.03% | 58.90% | |||
| SG&A Expenses | -0.20% | 28.59% | |||
| Depreciation & Amortization | 4.60% | -0.06% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.43% | 9.76% | |||
| Operating Income | 43.54% | -14.76% | |||
| Income Before Tax | 38.70% | -67.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.57% | -66.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.57% | -66.75% | |||
| EBIT | 43.54% | -14.76% | |||
| EBITDA | 46.41% | -15.54% | |||
| EPS Basic | 3.83% | -46.16% | |||
| Normalized Basic EPS | 45.56% | -47.03% | |||
| EPS Diluted | 3.83% | -46.16% | |||
| Normalized Diluted EPS | 45.56% | -47.03% | |||
| Average Basic Shares Outstanding | 11.85% | 14.10% | |||
| Average Diluted Shares Outstanding | 11.85% | 14.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
